{"version":"1.0","type":"link","title":"Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).","author_name":"Bilen MA 외","author_url":"https://prs-insight.online/author/Bilen%20MA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/134285","thumbnail_width":1200,"thumbnail_height":630}